Abstract

Gender and postoperative surgical margin status in MIBC: An analysis of the National Cancer Database.

Author
person Olivia French Gordon George Washington University Hospital, Washington, DC info_outline Olivia French Gordon, Michael Joseph Whalen
Full text
Authors person Olivia French Gordon George Washington University Hospital, Washington, DC info_outline Olivia French Gordon, Michael Joseph Whalen Organizations George Washington University Hospital, Washington, DC, George Washington University School of Medicine, Washington, DC Abstract Disclosures Research Funding No funding received None. Background: Women with muscle-invasive bladder cancer (MIBC) continue to experience persistent disparities in health outcomes despite accounting for less than 1/3 of newly diagnosed bladder cancer cases. Multiple studies have acknowledged the aggressive profile of female bladder cancer. This study aims to identify tangible areas to intervene and improve the delivery of oncologic care. Methods: The National Cancer Database (NCDB) was queried from 2004-2017 to conduct a retrospective cohort analysis of men and women with MIBC (cT2a-T4). N=41,037 patients with MIBC were reviewed, (30,313 male; 10,724 female). The primary endpoints were OS and surgical margin status. Logistic regression was performed to determine whether female sex conferred differential impact on surgical margin status when controlling for baseline clinical stage, age, receipt of neoadjuvant chemotherapy (NAC), Charleson-Deyo Comorbidity Classification (CDCC), and facility type. Cox proportional hazards assessed the impact of age, gender, margin status, CDCC and NAC on OS. Results: Logistic regression showed that sex, age, baseline clinical stage, CDCC, facility type and NAC were significant predictors of surgical margin status (p<.001). Female sex was found to have a 14.4% higher probability of having positive residual margins (HR 1.144 (95% CI: 1.07-1.23), p<.001). When adjusting for age, margin status, CDCC and NAC, Female gender (OS HR 1.063 (95% CI: 1.03-1.09), p<.001), positive microscopic margins (OS HR 2.0 (95% CI: 1.90-2.10), p<.001) and positive macroscopic margins (OS HR 2.62 (95% CI: 2.40-2.90), p<.001) independently portended poorer OS and necessitated increased adjuvant XRT (p<.001). Unexpected demographic findings included a significantly greater number of females than expected with a median household income <$38,000 (p= 0.047) and a greater number of females in the upper quartile of patients without a HS diploma (p<.001). The median days from diagnosis to definitive surgical treatment was significantly lower compared to males (58 vs 67 days; p<.001). Conclusions: Women with MIBC faced obstacles to getting treatment (less education and lower median income). Despite these hurdles they may be more proactive with their health as seen by a shorter time from diagnosis to the surgical table. However, this proactivity has yet to pay off as women undergoing surgical treatment for MIBC were significantly less likely to have clear margins post-operatively. The urologic community must mirror female patient’s proactivity and further investigate the gender disparity in surgical treatment of MIBC. Males Females Median Age 73 75 Clinical Stage: T2 24,100 (79.5%) 8,163 (76.1%) T3 3,721 (12.3%) 1,702 (15.9%) T4 2,492 (8.2%) 859 (8.0%) AJCC pN+ 8210 (25%) 3135 (26.5%) Positive Margins 2020 (6.7%) 820 (7.6%) NAC 6010 (19.4%) 1925 (17.5%)

2 organizations

1 drug

1 target